058820 — CMG Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapSucker Stock

Annual income statement for CMG Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	69,475	82,197	93,907	99,100	105,229
Cost of Revenue
Gross Profit	33,451	40,901	43,703	45,720	60,933
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	66,275	79,545	86,804	96,592	114,087
Operating Profit	3,200	2,652	7,103	2,508	-8,858
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,549	-1,255	6,731	2,880	-11,839
Provision for Income Taxes
Net Income After Taxes	3,165	-388	6,455	2,695	-10,077
Net Income Before Extraordinary Items
Net Income	3,165	-388	6,455	2,695	-10,077
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,165	-388	6,983	2,695	-10,077
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	12.9	-1.15	20.3	9.46	-46.6
Dividends per Share